presented by geertjan van tienhoven at 2018 asco ......geertjan van tienhoven, amc baseline...

13

Preoperative radiochemotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC) : <br />A randomized, controlled, multicenter phase III trial of the<br /> Dutch Pancreatic Cancer Group Presented By Geertjan Van Tienhoven at 2018 ASCO Annual Meeting

Upload: others

Post on 01-Jun-2020

1 views

Category:

Documents

0 download

Report

Download

Embed Size (px):

TRANSCRIPT

Page 1: Presented By Geertjan Van Tienhoven at 2018 ASCO ......Geertjan van Tienhoven, AMC baseline characteristics Preop. Radiochemotherapy n=119 65 (33-80) Median age (range) WHO PS 0-1

Preoperative radiochemotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC) : <br />A randomized, controlled, multicenter phase III trial of the<br /> Dutch Pancreatic Cancer Group

Presented By Geertjan Van Tienhoven at 2018 ASCO Annual Meeting

Page 2: Presented By Geertjan Van Tienhoven at 2018 ASCO ......Geertjan van Tienhoven, AMC baseline characteristics Preop. Radiochemotherapy n=119 65 (33-80) Median age (range) WHO PS 0-1

Rationale

Presented By Geertjan Van Tienhoven at 2018 ASCO Annual Meeting

Page 3: Presented By Geertjan Van Tienhoven at 2018 ASCO ......Geertjan van Tienhoven, AMC baseline characteristics Preop. Radiochemotherapy n=119 65 (33-80) Median age (range) WHO PS 0-1

Trial design

Presented By Geertjan Van Tienhoven at 2018 ASCO Annual Meeting

Page 4: Presented By Geertjan Van Tienhoven at 2018 ASCO ......Geertjan van Tienhoven, AMC baseline characteristics Preop. Radiochemotherapy n=119 65 (33-80) Median age (range) WHO PS 0-1

Trial design

Presented By Geertjan Van Tienhoven at 2018 ASCO Annual Meeting

Page 5: Presented By Geertjan Van Tienhoven at 2018 ASCO ......Geertjan van Tienhoven, AMC baseline characteristics Preop. Radiochemotherapy n=119 65 (33-80) Median age (range) WHO PS 0-1

Accrual

Presented By Geertjan Van Tienhoven at 2018 ASCO Annual Meeting

Page 6: Presented By Geertjan Van Tienhoven at 2018 ASCO ......Geertjan van Tienhoven, AMC baseline characteristics Preop. Radiochemotherapy n=119 65 (33-80) Median age (range) WHO PS 0-1

baseline characteristics

Presented By Geertjan Van Tienhoven at 2018 ASCO Annual Meeting

Page 7: Presented By Geertjan Van Tienhoven at 2018 ASCO ......Geertjan van Tienhoven, AMC baseline characteristics Preop. Radiochemotherapy n=119 65 (33-80) Median age (range) WHO PS 0-1

Results

Presented By Geertjan Van Tienhoven at 2018 ASCO Annual Meeting

Page 8: Presented By Geertjan Van Tienhoven at 2018 ASCO ......Geertjan van Tienhoven, AMC baseline characteristics Preop. Radiochemotherapy n=119 65 (33-80) Median age (range) WHO PS 0-1

Overall survival (ITT)

Presented By Geertjan Van Tienhoven at 2018 ASCO Annual Meeting

Page 9: Presented By Geertjan Van Tienhoven at 2018 ASCO ......Geertjan van Tienhoven, AMC baseline characteristics Preop. Radiochemotherapy n=119 65 (33-80) Median age (range) WHO PS 0-1

Disease free survival

Presented By Geertjan Van Tienhoven at 2018 ASCO Annual Meeting

Page 10: Presented By Geertjan Van Tienhoven at 2018 ASCO ......Geertjan van Tienhoven, AMC baseline characteristics Preop. Radiochemotherapy n=119 65 (33-80) Median age (range) WHO PS 0-1

Metastases and local recurrence (ITT)

Presented By Geertjan Van Tienhoven at 2018 ASCO Annual Meeting

Page 11: Presented By Geertjan Van Tienhoven at 2018 ASCO ......Geertjan van Tienhoven, AMC baseline characteristics Preop. Radiochemotherapy n=119 65 (33-80) Median age (range) WHO PS 0-1

Subset analysis

Presented By Geertjan Van Tienhoven at 2018 ASCO Annual Meeting

Page 12: Presented By Geertjan Van Tienhoven at 2018 ASCO ......Geertjan van Tienhoven, AMC baseline characteristics Preop. Radiochemotherapy n=119 65 (33-80) Median age (range) WHO PS 0-1

Conclusion

Presented By Geertjan Van Tienhoven at 2018 ASCO Annual Meeting

Page 13: Presented By Geertjan Van Tienhoven at 2018 ASCO ......Geertjan van Tienhoven, AMC baseline characteristics Preop. Radiochemotherapy n=119 65 (33-80) Median age (range) WHO PS 0-1

Acknowledgements

Presented By Geertjan Van Tienhoven at 2018 ASCO Annual Meeting

Retrospective Study of Neoadjuvant Versus Adjuvant ... · Radiochemotherapy in Locally Advanced Noninflammatory Breast Cancer Survival Advantage in cT2 Category by Neoadjuvant Radiochemotherapy*

VIVO: Creating a virtual community to foster interdisciplinary research Or how Leibniz, Ans & Ari van Tienhoven, and Tim Berners-Lee helped us do it. Janet

EUROPEAN SOCIETY FOR HYPERTHERMIC … · EUROPEAN SOCIETY FOR HYPERTHERMIC ONCOLOGY (ESHO) COUNCIL: G.C. van Rhoon (The Netherlands), GJ van Tienhoven (The Netherlands), …

Final report to Van Tienhoven Foundation and Megapode ... · Final report to Van Tienhoven Foundation and Megapode Specialist Group│1 November 2004 4 Figure 1. Waigeo and key localities

Creating Modular CRUD Desktop Applications Jiri Rechtacek Geertjan Wielenga

Forgotten Kingdoms - Van Tienhoven Foundation · Forgotten Kingdoms. Forgotten Kingdoms Proceedings of a seminar on the conservation of small and hidden species at the occasion of

Fotopresentatie Laan van Niftarlake 121 - Tienhoven

Lead with Data - Qlik · According to Geertjan Woltjes, Quooker’s Chief Operating Officer, employees empowered with data perform their job roles better which helps the organization

Nodes & Explorer Views - edu.netbeans.org · Nodes & Explorer Views Geertjan Wielenga Sun Microsystems. Certified Engineer Course Agenda ... • Hierarchy • Extensible • Rich

NetBeans Platform in 5.0 · PDF fileNetBeans Platform in 5.0: Radically simplified rich-client application & plug-in module development environment. Why? What? How? Where? Geertjan

Diffusion weighted magnetic resonance imaging for ... · 1Radiation Oncology, UMC Utrecht, Utrecht, Netherlands Introduction Radiochemotherapy (RCT) followed by total mesorectal excision

JavaCro'15 - Everything a Java EE Developer needs to know about the JavaScript Landscape - Geertjan Wielenga

RADIO- AND RADIOCHEMOTHERAPY OF HEAD AND ......tonsilla, tonsillar arch, palatum molle, uvula, lateral and + posterior paharyngeal wall, base of tongue HYPOPHARYNX sinus pyriformis,

Preoperative Chemoradiotherapy Versus Immediate Surgery ... · Casper H. van Eijck, MD, PhD2; and Geertjan van Tienhoven, MD, PhD1 for the Dutch Pancreatic Cancer Group abstract PURPOSE

An Enterprise Ready Technology In A Fast ... - 2016.javacro.hr · Copyright © 2014, Oracle and/or its affiliates. All rights reserved. Geertjan Wielenga. Created Date: 12/15/2015

Introduction to the NetBeans Platform Certified Training ... · PDF fileIntroduction to the NetBeans Platform Certified Training Course Geertjan Wielenga Sun Microsystems. ... Nokia

Coding for desktop and mobile with HTML5 and Java EE 7 - Geertjan Wielenga

SYRIAN SOCIABLE LAPWING SURVEY - Van Tienhoven …SYRIAN SOCIABLE LAPWING SURVEY 18 February - 5 March 2007 Remco Hofland & Guido Keijl Foundation Working Group International Waterbird-

Geertjan Wielenga e John Brock - JavaScript empresarial com o Oracle JavaScript extension toolkit - #JavaOneBR #oowBR

Studies of Radiochemotherapy in an Orthotopic Cervix ... · PDF fileStudies of Radiochemotherapy in an Orthotopic Cervix Cancer Model. R.P. Hill, N. Chaudary, D.W. Hedley, S, Jelveh,

NetBeans Platform Compared with Eclipse Rich Client PLatform Kai Tödter, Siemens AG Geertjan Wielenga, Sun Microsystem ID# ????

Intraday liquidity management, Geertjan van Bochove, SWIFT

Project group D. Project Team Delta Lars van den Broek Bastiaan Rusch Jan-Willem de Vogel Niels Hamoen Sander van Tienhoven Benjamin Wennink

An Enterprise Ready Technology In A Fast Changing ...Oracle+JET+Wieleng… · Copyright © 2014, Oracle and/or its affiliates. All rights reserved. Geertjan Wielenga. Created Date:

MVC 1.0 Manfred Riem (@mnriem) Oracle Geertjan Wielenga (@geertjanw) Oracle Copyright © 2014, Oracle and/or its affiliates. All rights reserved. |

NetBeans Platform Compared with Eclipse Rich Client … · NetBeans Platform Compared with Eclipse Rich Client PLatform Kai Tödter, Siemens AG Geertjan Wielenga, ... Both, Eclipse

Rectal Cancer - Preop. Radiochemotherapy and Postop. Chemotherapy

Rare Disease Day 2019 - VSOP · PowerPoint-presentatie Author: Zonneveld van G. \(Geertjan\) Created Date: 3/19/2019 2:12:11 PM

Web Frameworks and Tooling - NetBeans · Web Frameworks and Tooling What is it? How do I use it? And why should I want to? Geertjan Wielenga Sun Microsystems Source Talk Tage

V. Budach – Statements on H&N Cancer - 1 Discussion Panel on Primary Radiochemotherapy Volker Budach, MD, PhD Head Department for Radiation Oncology Charité

Perfusion CT and radiochemotherapy in head and neck cancer · Head and neck cancer (HNC) is the fifth most common cancer worldwide accounting for ap-proximately 5% of all tumours1,2

Theranostics › ms › doc › 1685 › epub › 41239t2.docx · Web viewArch Otolaryngol Head Neck Surg. 2002; 128: 241-6. 37.Donker M, van Tienhoven G, Straver ME, Meijnen P, van

Overview of the Indications and Contraindications for ...perspectivesinmedicine.cshlp.org/content/4/5/a015602.full.pdf · radiochemotherapy and liver transplantation have established

Statements on Head and Neck Cancer 2006 Primary Radiochemotherapy Arlene A. Forastiere, M.D. Johns Hopkins University School of Medicine Department of

JavaCro'14 - Consuming Java EE Backends in Desktop, Web, and Mobile Frontends – Geertjan Wielenga